1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsThis funding opportunity supports research, development, and pre-pilot testing intended to lower production costs, improve performance, reduce reliance on imports, and accelerate the commercialization of domestically produced chemicals.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: State and local governments, federally recognized Tribal governments, for-profit businesses, small businesses, nonprofit organizations, and public or private institutions of higher education. Confirm the full requirements in the official notice before applying.
The current listing shows up to $58 million total funding anticipated. Verify award ceilings, matching requirements, and allowable costs in the official notice.
The published deadline was September 1, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
Accelerating Scale-up and Pre-piloting of Emerging Chemical Technologies (ASPECT) is funded by Department of Energy (DOE). Verify program details on the funder's official page before applying.
Past winners and funding trends for this program
From lab to market: Strengthening the role of Technology Transfer Offices in bringing knowledge to the market is sponsored by European Commission — Horizon Europe. Expected Outcome: Project results are expected to contribute to the following outcomes: Increased commercialisation of academic research results, by facilitating access for industry, startups and scaleups to the intellectual assets of academic research; Strengthened collaboration between industry and academia, reflected in an increased number of technology transfer deals and joint R&D projects resulting in market-ready innovations; Introduced more startup friendly intellectual asset transfer/licensing policies in universities/research and higher education institutions/RTOs; Increased number of spinoffs by enabling researchers to overcome the barriers to commercialising their intellectual assets; Reduced transaction costs related to Intellectual Property Rights (IPR) negotiations by establishing more standardised asset transfer policies across universities/research and higher education institutions/RTOs; Optimised transfer/licensing processes by universities/research and higher education institutions/RTOs based on grouping intellectual assets in portfolios that can be commercialised in package deals that are more attractive for industry and investors. Scope: Academic knowledge producing organisations (universities, research and higher education institutions and RTOs) are acting as innovation engines by fuelling startups and industries with new knowledge, technologies and skilled individuals. This potential can be nurtured with efficient intellectual management strategies and effective Technology Transfer Offices (TTOs). However, Europe’s potential of research valorisation is underutilised. Currently, it is challenging for industrial actors to identify and access academic results that have potential for commercialisation. On the one hand, a relatively complex fragmented landscape of TTOs generates high transaction costs discouraging companies, especially startups from engaging in collaboration or accessing academic research for commercialisation. On the other hand, the lack of financial and non-financial incentives for academic researchers hampers their commitment. Indeed, in many cases, researchers cannot fully appropriate royalties from the licensing of intellectual assets and knowledge valorisation activities are not recognised for their career progression. In this regard, the Draghi report [1] recommends European universities/RTOs to adopt a more coordinated, commercialisation minded, and startup friendly intellectual asset management approach [2] . Participating beneficiaries should engage in the following activities: adopting startup-friendly intellectual asset management strategies; accelerating the commercialisation of academic research results under fair and transparent conditions in an attractive way for innovative companies and investors, in particular for critical technology areas related to the EU’s economic security; reinforcing the adoption of best practices in intellectual asset management [3] including the equitable sharing of value generated in R&I activities; improving the support to researchers and students in commercialising research results; enhancing intellectual asset management practices by establishing portfolio approaches to market intellectual assets in package deals; facilitating the collaboration between researchers, startups and innovative companies. More specifically, project participants should: Identify and share best-practices developed to support knowledge valorisation [4] ; On this basis, create a common set of tools for start-up friendly licensing/transfer [5] to be adapted to the specific national/regional context with templates, strategies, successful case studies and business models. The toolbox could include standardised rules and processes together with flexible and adaptable clauses to support negotiation, conclusion and implementation of licensing agreements; Develop a common incentives and benefit-sharing model ensuring incentives for researchers and students to engage in com Programme areas: Horizon Europe (HORIZON), Innovative Europe, European innovation ecosystems Keywords: IPR management, Market-creating innovation, Technology transfer
IHI European HealthCare Incubator Network is sponsored by European Commission — Horizon Europe. Expected Impact: The action under this topic is expected to achieve the following impacts and contribute to the following EU policies/initiatives: deliver innovative, early technology solutions that contribute to addressing strategic unmet public health needs across multiple therapy areas to improve prevention, early diagnosis, and treatment; leverage the unique network and scale of IHI JU members to create a pipeline to support innovative startups in the health industry, fully integrated into European initiatives in support of start-ups and entrepreneurship; drive early cross-sector health R&D and innovation to strengthen the European healthcare industry’s global competitiveness, contributing to the EU Industrial Strategy and Pharmaceutical Strategy objectives; create a sustainable network of European healthcare incubators to guide and support highly talented and innovative early-stage companies; harness digital health and data-sharing technologies (e.g., AI and big data) to enable interoperable health solutions, contributing to the European Health Data Space (EHDS) and improved evidence based care;- the action should generate a portfolio of early‑stage companies that have undergone rigorous multi‑industry validation, significantly increasing their credibility with investors, regulators, and healthcare systems. This ‘industry quality seal’ should enhance the selected startups’ ability to secure follow‑on financing; by integrating corporate expertise into a pan‑European incubator network, the action should reduce fragmentation, support faster clinical and eventually commercial decision‑making, and enable more innovators to navigate regulatory and reimbursement pathways successfully. This should contribute to the objectives of the EU to accelerate the translation of research into deployable health technologies. The Network should serve as a feeder mechanism into wider EU support structures, ensuring that promising companies can transition smoothly into later‑stage funding and scale‑up opportunities. This complementarity should maximise the added value of EU public funding while avoiding duplication and reinforcing Europe’s position as a globally competitive hub for health innovation. The action under this topic should synergise with relevant EU programmes and contribute to several key EU strategies and policies: Life Science strategy, the proposed Biotech Act (especially the biotechnology development accelerators as referred to in article 5 of the Commission proposal), Industrial strategy, Pharmaceutical strategy, EU4Health Programme, Digital Europe Programme, Testing and Experimental Facility for Health AI and Robotic (TEF-Health), European Innovation Council (EIC) programmes, EU Competitive Compass, Choose Europe initiative, Startup and Scale-up strategy by the European Commission. Additionally, the action under this topic should synergise with the forthcoming European Startup and Scaleup Hubs and, in particular, encourage connection into the Network from the Call ‘European Startup and Scaleup Hub Pilot Call – HORIZON-EIE-2026-02-CONNECT-01’. Furthermore, the action has the potential to support Europe’s Beating Cancer Plan, EU Mission on Cancer, Healthier Together – EU Non-Communicable diseases initiative, Joint Action for Cardiovascular Disease and Diabetes in Europe, or the Cardiovascular Health Plan. Applicants should demonstrate in the proposal how these synergies will avoid duplication, ensure complementarity with existing EU efforts, and provide early-stage companies with continuity and scale up pathways. Expected Outcome: This call topic responds to the pressing need for a collaborative approach to accelerating the research-to-market pathway and fostering innovation and competitiveness in the European healthcare sector. Accordingly, the action under this topic must contribute to all of the following outcomes: 1. A sustainable European HealthCare Incubator Network (hereafter, the ‘Network’) linking incubators from t Programme areas: Global Challenges and European Industrial Competitiveness, Health, Innovative Health Initiative, Horizon Europe (HORIZON) Keywords: Competitiveness, innovation, research and development, Decrease technological and industrial risks, Health care, Incubator companies, Investment readiness, Related to SME and start-up support, SME support, Start-up companies, European HealthCare Incubator Network, IHI, IHI JU, Innovative Health Initiative, Innovative Health Initiative Joint Undertaking, Joint Undertaking Deadline stages: 2026-10-08, 2027-04-21
On September 21, 2026 DOE selected 21 projects under DE-FOA-0003472 — five EGS field tests and 16 exploration wells — for up to $99 million of a $171.5 million authorization. The solicitation is structured to reopen for up to 72 months on roughly annual cycles. Here is how to position for the next one.
Read articleDOE named 31 grid projects across 26 states for $1.9B on September 24, 2026. Recipients bring $3.35B of their own money. Here is what the selection list reveals about how to win the next GRIP round.
Read articleThe DOE Quantum Genesis Q Competition (DE-FOA-0003657) posted September 17, 2026 with an October 19 deadline. Phase I pays $250,000 then $1.25M on milestones; Phase II is a $100M pool plus two $50M bonus pools at 150 and 200 logical qubits. It is an Other Transaction Agreement, not a grant.
Read article